Abstract:Human triple negative breast cancer cells, MDA-MB-231, show typical epithelial to mesenchymal transition associated with cancer progression. Mitochondria play a major role in cancer progression, including metastasis. Changes in mitochondrial architecture affect cellular migration, autophagy and apoptosis. Silibinin is reported to have anti-breast cancer effect. We here report that silibinin at lower concentrations (30–90 μM) inhibits epithelial to mesenchymal transition (EMT) of MDA-MB-231, by increasing the expression of epithelial marker, E-cadherin, and decreasing the expression of mesenchymal markers, N-cadherin and vimentin. Besides, silibinin inhibition of cell migration is associated with reduction in the protein expression of matrix metalloproteinases 2 and 9 (MMP2 and MMP9) and paxillin. In addition, silibinin treatment increases mitochondrial fusion through down-regulating the expression of mitochondrial fission-associated protein dynamin-related protein 1 (DRP1) and up-regulating the expression of mitochondrial fusion-associated proteins, optic atrophy 1, mitofusin 1 and mitofusin 2. Silibinin perturbed mitochondrial biogenesis via down-regulating the levels of mitochondrial biogenesis regulators including mitochondrial transcription factor A (TFAM), peroxisome proliferator-activated receptor gamma coactivator (PGC1) and nuclear respiratory factor (NRF2). Moreover, DRP1 knockdown or silibinin inhibited cell migration, and MFN1&2 knockdown restored it. Mitochondrial fusion contributes to silibinin's negative effect on cell migration. Silibinin decreased reactive oxygen species (ROS) generation, leading to inhibition of the NLRP3 inflammasome activation. In addition, knockdown of mitofusin 1&2 (MFN 1&2) relieved silibinin-induced inhibition of NLRP3 inflammasome activation. Repression of ROS contributes to the inhibition of the expression of NLRP3, caspase-1 and IL-β proteins as well as of cell migration. Taken together, our study provides evidence that silibinin impairs mitochondrial dynamics and biogenesis, resulting in reduced migration and invasion of the MDA-MB-231 breast cancer cells.

Involvement of Estrogen Receptors in Silibinin Protection of Pancreatic Β-Cells from TNFα- or IL-1β-induced Cytotoxicity.

Silibinin Protects Rat Pancreatic Beta-Cell Through Up-Regulation Of Estrogen Receptors' Signaling Against Amylin- Or A Beta(1-42)-Induced Reactive Oxygen Species/Reactive Nitrogen Species Generation

Attenuating Effect of Silibinin on Palmitic Acid-Induced Apoptosis and Mitochondrial Dysfunction in Pancreatic Β-Cells is Mediated by Estrogen Receptor Alpha

Ginsenoside Rg1 Improves Inflammation and Autophagy of the Pancreas and Spleen in Streptozotocin-Induced Type 1 Diabetic Mice.

[Protective effect of silibinin on islet β cells in C57BL/6J mice fed a highfat diet]

The Protective Effects of Silibinin in the Treatment of Streptozotocin-Induced Diabetic Osteoporosis in Rats

Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of mitochondrial fusion

Protective effects of silibinin against ethanol- or acetaldehyde-caused damage in liver cell lines involve the repression of mitochondrial fission

Celastrol inhibits TXNIP expression to protect pancreatic β cells in diabetic mice

Silibinin decreases hepatic glucose production through the activation of gut-brain-liver axis in diabetic rats

Silibinin induces immunogenic cell death in cancer cells and enhances the induced immunogenicity by chemotherapy

Silibinin Induces Apoptosis Through Inhibition of the Mtor-Gli1-bcl2 Pathway in Renal Cell Carcinoma.

Research progress on the mechanism of silibinin in preventing and treating diabetes and its complications

Naringenin protects pancreatic β cells in diabetic rat through activation of estrogen receptor β

Effect of silibinin on ethanol- or acetaldehyde-induced damge of mouse primary hepatocytes in vitro

Targeting silibinin in the antiproliferative pathway.

Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells

Liposome Encapsulation Enhances the Antidiabetic Efficacy of Silibinin

Activation of PGC‐1α ‐dependent mitochondrial biogenesis supports therapeutic effects of silibinin against type I diabetic periodontitis

Epigallocatechin-3-gallate Protects Pro-Inflammatory Cytokine Induced Injuries in Insulin-Producing Cells Through the Mitochondrial Pathway.

Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells.